Controlling in and out - the future of interfering with immune cell trafficking in inflammatory bowel disease.

Autor:	Zundler S; Department of Medicine 1 and Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Schulze LL; Department of Medicine 1 and Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Neurath MF; Department of Medicine 1 and Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Jazyk:	angličtina
Zdroj:	Expert review of clinical immunology [Expert Rev Clin Immunol] 2023 Feb; Vol. 19 (2), pp. 155-167. Date of Electronic Publication: 2022 Dec 05.
DOI:	10.1080/1744666X.2023.2152794
Abstrakt:	Introduction: Immune cell trafficking is a key requirement in the pathogenesis of inflammatory bowel diseases. Consistently, therapeutic strategies to target immune cell trafficking have been established and continue to be developed for the treatment of ulcerative colitis and Crohn's disease. Areas Covered: In this review, we briefly summarize the most important checkpoints of intestinal immune cell trafficking and their importance during IBD. Moreover, we provide an overview of associated therapeutic targets and previous as well as current efforts on treatment strategies related to these targets. Expert Opinion: Finally, we comment on potential future developments that might shape the field of immune cell trafficking in the context of IBD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu